Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A new fully closed automated banking process for healthy autologous cells to standardize the starting material for CAR T manufacturing.

Molecular therapy. Advances·2026

Same author

Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025

Same author

Engineering of BZ transposase and transposon donor vector for enhanced efficiency and safety in gene delivery applications.

Nucleic acids research·2025

Same author

Cryopreserved leukapheresis enables scalable and distributed CAR-T manufacturing: a multi-platform comparative study.

Scientific reports·2025

Same author

Low-liver-accumulation lipid nanoparticles enhance the efficacy and safety of HPV therapeutic tumor vaccines.

Journal of translational medicine·2025

Same author

Recent progress in stem cell and immune cell-based interventions for aging and age-related disorders.

Frontiers in aging·2025

Search research articles

Related Experiment Video

Updated: Nov 23, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Current Progress in CAR-T Cell Therapy for Hematological Malignancies.

Donglei Han¹, Zenghui Xu^1,2,3, Yuan Zhuang³

¹Henan Cell Therapy Group Co. LTD, Zhengzhou, Henan, China.

Journal of Cancer

|January 4, 2021

Summary

Chimeric antigen receptor T (CAR-T) cell therapy shows promise for hematologic cancers, with approved treatments available. Further research is needed to address toxicities and knowledge gaps for broader application.

Keywords:

CAR-T cells therapy hematological malignancies safety strategies

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Related Experiment Videos

Last Updated: Nov 23, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Area of Science:

Oncology
Immunology
Biotechnology

Background:

Immunotherapies like monoclonal antibodies and checkpoint inhibitors demonstrate significant anti-cancer effects.
Chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for hematological malignancies, with several therapies approved since 2017.

Purpose of the Study:

To review the current status and future trends of CAR-T cell therapy in hematological neoplasms.
To concentrate on CAR-T technologies, applications, adverse effects, and safety measures.

Main Methods:

Literature review focusing on CAR-T cell therapy in hematological neoplasms.
Analysis of approved CAR-T therapies, including Kymriah, Yescarta, and Tecartus.
Examination of CAR-T technology, clinical applications, toxicities, and safety protocols.

Main Results:

CAR-T cell therapy has achieved encouraging results in treating various hematologic tumors.
Approved CAR-T therapies include Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), and Tecartus (brexucabtagene autoleucel).
Challenges remain regarding the toxicities and knowledge gaps associated with CAR-T cell therapy.

Conclusions:

CAR-T cell therapy holds potential for improved safety and efficacy in treating hematologic tumors.
CAR-T cell therapy may become a mainstream therapeutic option for eliminating hematologic malignancies.
Continued research is essential to optimize CAR-T cell therapy and mitigate adverse effects.